Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 30th June 2019. The Company's cash plus term deposits at the end of the quarter stood at $5.4m. On 30th June 2019, the Company had cash at bank of $1,360,086 and $4,050,000 in term deposits. Expenditure during the quarter was in line with forecast.
Anatara Lifesciences Ltd
Anatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.
Anatara's CEO, Steve Lydeamore will be presenting to investors during the Bioshares Biotech Summit this Friday, and at a Monsoon Communications Twilight Investor Briefing event in Melbourne during August.
PAC Partners Equity Research has released its latest research and valuation report on Anatara Lifesciences (ASX:ANR). The report provided a SPEC BUY rating and a 12-month price target of $0.90 per share.
Anatara Lifesciences (ASX:ANR) provides an update on the strategic evaluation of Detach(R), its non-antibiotic animal health asset which aids in the control of diarrhoeal disease in piglets with potential application in other livestock animals, aquaculture and companion animals.
Anatara Lifesciences (ASX:ANR) releases the presentation which Chief Executive Officer, Mr Steven Lydeamore, will present to investors in Perth this week and to the Gold Coast Investment Showcase later this month.
Anatara Lifesciences (ASX:ANR) announces that Zoetis Inc. has given notice of termination of the exclusive worldwide license of Detach(R) for livestock and horses. Zoetis made a portfolio decision not to continue with the pursuit of this asset.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to invite existing and potential shareholders to attend an information briefing session in Perth to discuss the Company's work in gastrointestinal health and to meet Chief Executive Officer, Steven Lydeamore.
In the lead up to World IBD Day, this coming Sunday, 19th May, PAC Partners Equity Research has released its latest research and valuation report on Anatara Lifesciences (ASX:ANR). The report provided a BUY rating and a 12-month price target of $1.40 per share.
The month of May marks two very important days in the IBD calendar - Crohn's and Colitis Awareness Month, which takes place throughout May and World IBD Day, which is being held this Sunday, 19 May. Both events are designed to raise awareness for Crohn's disease and Ulcerative colitis, and show support to the 10 million people worldwide who live with IBD.
While in Sydney last month, Anatara Lifesciences (ASX:ANR) CEO Steve Lydeamore sat down with Anna Napoli at Finance News Network, Australia's largest provider of online business and finance news.